Cyp1a2(-/-) null mutant mice develop normally but show deficient drug metabolism

被引:132
作者
Liang, HCL
Li, H
McKinnon, RA
Duffy, JJ
Potter, SS
Puga, A
Nebert, DW
机构
[1] UNIV CINCINNATI,MED CTR,DEPT ENVIRONM HLTH,CINCINNATI,OH 45267
[2] UNIV CINCINNATI,CHILDRENS HOSP,MED CTR,DIV BASIC SCI RES,CINCINNATI,OH 45229
[3] UNIV CINCINNATI,MED CTR,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267
关键词
cytochrome P450; embryonic stem cells; arylamine carcinogenesis;
D O I
10.1073/pnas.93.4.1671
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Cytochrome P450 1A2 (CYP1A2) is a predominantly hepatic enzyme known to be important in the metabolism of numerous foreign chemicals of pharmacologic, toxicologic, and carcinogenic significance. CYP1A2 substrates include aflatoxin B-1, acetaminophen, and a variety of environmental arylamines. To define better the developmental and metabolic functions of this enzyme, we developed a CYP1A2-deficient mouse line hy homologous recombination in embryonic stem cells. Mice homozygous for the targeted Cyp1a2 gene, designated Cyp1a2(-/-), are completely viable and fertile; histologic examination of 15-day embryos, new-born pups, and 3-week-old mice revealed no abnormalities. No CYP1A2 mRNA was detected by Northern blot analysis. Moreover, mRNA levels of Cyp1a1, the other gene in the same subfamily, appear unaffected by loss of the Cyp1a2 gene. Because the muscle relaxant zoxazolamine is a known substrate for CYP1A2, we studied the Cyp1a2(-/-) genotype by using the zoxazolamine paralysis test: the Cyp1a2(-/-) mice exhibited dramatically lengthened paralysis times relative to the Cyp1a2(+/+) wild-type animals, and the Cyp1a2(+/-) heterozygotes showed an intermediate effect. Availability of a viable and fertile CYP1A2-deficient mouse line will provide a valuable tool for researchers wishing to define the precise role of CYP1A2 in numerous metabolic and pharmacokinetic processes.
引用
收藏
页码:1671 / 1676
页数:6
相关论文
共 43 条
[21]  
LI H, 1996, IN PRESS EMBO J
[22]  
LIANG HC, 1995, TOXICOLOGIST, V15, P59
[23]  
LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K
[24]  
Nebert D W, 1994, Prog Liver Dis, V12, P63
[25]   DRUG-METABOLISM - GROWTH SIGNAL PATHWAYS [J].
NEBERT, DW .
NATURE, 1990, 347 (6295) :709-710
[26]   PROPOSED ROLE OF DRUG-METABOLIZING-ENZYMES - REGULATION OF STEADY-STATE LEVELS OF THE LIGANDS THAT EFFECT GROWTH, HOMEOSTASIS, DIFFERENTIATION, AND NEUROENDOCRINE FUNCTIONS [J].
NEBERT, DW .
MOLECULAR ENDOCRINOLOGY, 1991, 5 (09) :1203-1214
[27]  
NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.bi.56.070187.004501
[28]   DRUG-METABOLIZING-ENZYMES IN LIGAND-MODULATED TRANSCRIPTION [J].
NEBERT, DW .
BIOCHEMICAL PHARMACOLOGY, 1994, 47 (01) :25-37
[30]  
NELSON DR, 1996, IN PRESS PHARMACOGEN, V6